---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-020824"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-05-20T23:59:59+00:00"
generated_at: "2026-06-25T08:50:45.490257+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FDA approves TherapeuticsMD's ANNOVERA sNDA, boosting supply by ~7,000 rings

## Summary
- FDA approved sNDA for ANNOVERA with revised in vitro release testing specification to allow normal manufacturing variability.
- Company expects ~7,000 additional rings to enter supply chain in Q2/Q3 2022, reducing batch rejections.
- CEO Hugh O'Dowd says approval enables scaling production to meet increasing customer demand for procedure-free birth control.

## SEC filing metadata
- accession: 0001564590-22-020824
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-05-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459022020824/0001564590-22-020824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459022020824/txmd-8k_20220520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-020824
- JSON: https://secwatch.observer/filing/0001564590-22-020824.json
- Plain text: https://secwatch.observer/filing/0001564590-22-020824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.